Also called: GHRP, Ipamorelin and CJC-1295, Ipamorelin and CJC-1295 without DAC
Ipamorelin is a man-made peptide, which is a tiny chain of building blocks called amino acids. It is a copy of a natural body chemical called ghrelin, which is sometimes called the hunger hormone. Ipamorelin is sold as a white powder for lab studies. It is not an approved medicine. Companies sell it to researchers, and some people seek it out hoping it will help with muscle, recovery, and aging.
Ipamorelin tells the pituitary gland, a small gland in the brain, to let out growth hormone. Growth hormone helps the body build muscle and repair itself. Ipamorelin does this by attaching to a special docking spot on the gland's cells called the ghrelin receptor. This makes growth hormone come out in short bursts, much like the body does on its own. It is known for being very selective, meaning it raises growth hormone without raising other stress hormones.
There is still a lot we do not know. Most studies have been done in animals or in labs, not in large human trials. It is not approved by the FDA, so its safety and long-term effects in people are unclear. Some other similar peptides raise prolactin and cortisol, but ipamorelin causes little of this rise. Anyone thinking about using it should know it is meant for laboratory research only, and using unapproved injectable compounds carries real risks.
Building Blocks
Ipamorelin is one of the building blocks in this blend or stack people actually buy:
Natural growth-hormone release — recovery, body composition, sleep
Paired with CJC-1295
Established GH blend
Benefits
The main themes across 17 research studies, in plain language.
Studies indicate that increased growth hormone levels may support the development of lean muscle mass and improve overall body composition.
Evidence suggests that stimulation of growth hormone pathways may support bone mineralization, increase bone density, and promote skeletal growth.
Research suggests that this peptide stimulates the release of growth hormone in a pulsatile manner, mimicking natural patterns, without significantly elevating stress hormones like cortisol or prolactin.
Studies highlight a favorable safety profile, noting that the peptide selectively targets growth hormone release without significantly affecting cortisol, prolactin, or ACTH levels.
Research indicates that growth hormone release may accelerate the repair of damaged tissues, reduce muscle soreness, and support post-exercise recovery.
Evidence points to prokinetic properties that may accelerate gastric emptying and improve the movement of contents through the digestive tract.
Research points to a potential role in promoting lipid breakdown and reducing adipose tissue, which may aid in fat loss and weight management.
Findings imply that therapy may help regulate blood sugar levels and improve insulin sensitivity, though individual responses can vary.
Limited evidence suggests potential benefits for vascular health and improved blood flow, possibly linked to nitric oxide or metabolic changes.
Preliminary studies indicate potential neuroprotective benefits and improvements in cognitive function, possibly mediated through BDNF or other pathways.
Research suggests that cellular repair mechanisms and optimized hormone levels may contribute to anti-aging benefits and overall vitality.
Studies suggest that enhanced growth hormone levels may stimulate collagen production, potentially improving skin elasticity and connective tissue health.
Findings imply that therapy may improve sleep quality by increasing slow-wave (deep) sleep duration and reducing the time it takes to fall asleep.
Anecdotal reports and some studies suggest that users may experience improved energy levels, reduced anxiety, and an enhanced sense of well-being.
Research suggests that combining this peptide with other agents (like GHRH analogs) may create synergistic effects, amplifying growth hormone release.
See where Ipamorelin fits — the most-used combinations, dosing notes from the research, and what to check before you buy.
No spam. Unsubscribe anytime.
1 reported routine — each line links to the source it came from.
Self-reported & vendor-suggested
Routines shared by users and sellers in forums and product pages — anecdotal, not tested in clinical trials. We show them for completeness, not as a recommendation.
General
mg vs mcg: one milligram (mg) equals 1,000 micrograms (mcg) — multiply by 1,000 going from mg to mcg, divide by 1,000 going from mcg to mg. Mixing the two up is a thousand-fold dosing error: 1 mg taken instead of 1 mcg is a 1,000× overdose; 1 mcg instead of 1 mg is a 1,000× underdose. Always double-check the unit label and the decimal place.
Honest expectations
What the sourced research says it doesn’t do — as notable as what it does.
Safety
Adverse effects reported in the research and by community use.
Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
Ipamorelin is a synthetic pentapeptide, a third-generation growth hormone releasing peptide (GHRP) and selective agonist of the ghrelin/growth-hormone secretagogue receptor (GHS-R) on pituitary somatotropes. It stimulates pulsatile GH release while having minimal effect on ACTH, cortisol, or prolactin - the first relatively selective GH secretagogue. It is not FDA-approved.
Evidence
Every claim above traces back to a source you can check — here are 8 of them.
Ipamorelin, the first selective growth hormone secretagogue.
Ipamorelin for post-operative ileus (NCT00672074)
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.
Ipamorelin
Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats.
Ipamorelin | C38H49N9O5 | CID 9831659 - PubChem
Timeline
Key moments in Ipamorelin’s research and regulatory timeline — sourced and dated.
News
Dated, sourced reporting that mentions Ipamorelin.
A November 2025 CNN report documents how celebrities and wellness influencers are fueling mass consumer use of unapproved peptides like BPC-157, TB-500, ipamorelin, and CJC-1295, many sold with a "for research use only" label that lawyers and regulators describe as a loophole to evade FDA oversight. Health Secretary Robert F. Kennedy Jr. has vowed to end the agency's "war on peptides," while named sellers such as biohacker Gary Brecka market injectable vials for $350 to $600 each. Independent experts — including Scripps' Dr. Eric Topol and UC Davis biologist Paul Knoepfler — stress that none of these compounds have passed adequate clinical trials and that "research-grade" powders often contain contaminants. BPC-157 and TB-500 are also banned by international sports authorities as doping substances.
The FDA issued a warning letter to NuScience Peptides LLC for marketing unapproved injectable peptide drugs, including GLP-1/GLP-2/GLP-3 products and other peptides, on its website. The agency determined these products are unapproved new drugs under the FD&C Act. FDA warned that failure to correct the violations could lead to seizure or injunction.
The New Zealand Rugby Anti-Doping Judicial Committee decision records Customs-intercepted mail containing, among other items, Biotech peptides, CJC-1295 (ipamorelin) 5/5mg, 3 x vials — a single combination vial naming both peptides, which the committee lists as a prohibited non-specified substance. The source labels the vial CJC-1295 (ipamorelin) without further DAC qualification; it is attributed to the with-DAC compound because unqualified CJC-1295 denotes the DAC form. A recreational athlete received a two-year sanction (backdated to provisional suspension on 9 August 2023) for importing and using the prohibited substances.
FDA's running list of bulk drug substances that present significant safety risks in compounding names GHRP-2, GHRP-6, ipamorelin acetate, CJC-1295 and AOD-9604. GHRP-2 and GHRP-6 were added to the 503B risk list on September 29, 2023 over immunogenicity concerns, and FDA notes serious adverse events for CJC-1295 (increased heart rate, systemic vasodilatory reactions). The list confirms these peptides are treated by FDA as unsafe-for-compounding substances.
FDA warned Tailor Made Compounding LLC (Nicholasville, KY) after a 2018 inspection found it compounded drug products with bulk substances ineligible for 503A exemptions. The letter explicitly lists the compounded substances: Follistatin, GHRP-2, GHRP-6, AOD 9604, BPC 157, Bremelanotide (PT-141), Cerebrolysin, DSIP, Epitalon, GHK-Cu, Ipamorelin, LL-37, Melanotan II, Selank, Semax, and CJC 1295, among others. The firm was cited for insanitary aseptic processing (adulteration), unapproved new drugs, and misbranding, and removed GHRP-2 and GHRP-6 from its formulary in response.
Wondering how Ipamorelin pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →Explore by goal
Related peptides
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.